This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and health-related quality of life.
Study Type
OBSERVATIONAL
Enrollment
500
The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGProgression-free survival
Progression-free survival was defined as the time from the date of diagnosis until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.
Time frame: Baseline up to data cut-off (up to approximately 60 months)
Overall Response Rate
Percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria.
Time frame: End of treatment visit (approximately 6 months)
Complete Response Rate
Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.
Time frame: End of treatment visit (approximately 6 months)
Time to Next Treatment
From the start of treatment to the initiation of next-line treatment
Time frame: From the start of treatment to the initiation of next-line treatment (up to approximately 60 months)
Duration of Response
Time from first occurrence of documented complete response or partial response to disease progression/relapse, or death from any cause for participants, whichever occurs first.
Time frame: Baseline up to data cut-off (up to approximately 60 months)
Duration of Complete Response
Time from the first occurrence of a documented complete response to the date of progression, relapse, or death from any cause, whichever occurs first.
Time frame: Baseline up to data cut-off (up to approximately 60 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Overall survival
Overall survival was defined as the time from the date of diagnosis to the date of death from any cause.
Time frame: Baseline up to data cut-off (up to approximately 60 months)
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Baseline up to data cut-off (up to approximately 60 months)